Diverse product portfolio including phyto-based products developed in the Company with potential for growth in new markets

4 out of the top 10 products represent 41% of “Sopharma” AD sales revenues and are based on active pharmaceutical ingredients extracted from plants with unique therapeutic characteristics. These products were initially developed within the enterprise. The main reason for their exceptional performance is the good recognition of the brands on the export markets.

The established phyto products are attracting growing interest among our partners due to their potential for registration on new markets. Such an example is Tabex, on whose registration with FDA our partner Achieve Life Sciences Inc. (NASDAQ: ACHV) is working.

Top 5 phyto-products
Phyto product	Position in Top 15	Treatment
Carsil^TM	1	Liver diseases
Tabex^TM	2	Tobacco addiction
Tribestan^TM	9	Impotence & infertility
Nivalin^TM	5	Neurological disorders

Product Diversification